KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Charles River Laboratories International (CRL) over the last 16 years, with Q3 2025 value amounting to $54.4 million.

  • Charles River Laboratories International's Net Income towards Common Stockholders fell 2075.89% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.5 million, marking a year-over-year decrease of 12020.96%. This contributed to the annual value of $10.3 million for FY2024, which is 9783.05% down from last year.
  • Charles River Laboratories International's Net Income towards Common Stockholders amounted to $54.4 million in Q3 2025, which was down 2075.89% from $52.3 million recorded in Q2 2025.
  • Charles River Laboratories International's Net Income towards Common Stockholders' 5-year high stood at $189.1 million during Q4 2022, with a 5-year trough of -$215.7 million in Q4 2024.
  • Over the past 5 years, Charles River Laboratories International's median Net Income towards Common Stockholders value was $90.0 million (recorded in 2024), while the average stood at $79.4 million.
  • In the last 5 years, Charles River Laboratories International's Net Income towards Common Stockholders surged by 4894.19% in 2022 and then tumbled by 21529.53% in 2024.
  • Over the past 5 years, Charles River Laboratories International's Net Income towards Common Stockholders (Quarter) stood at $139.8 million in 2021, then skyrocketed by 35.24% to $189.1 million in 2022, then decreased by 1.07% to $187.1 million in 2023, then plummeted by 215.3% to -$215.7 million in 2024, then skyrocketed by 125.23% to $54.4 million in 2025.
  • Its last three reported values are $54.4 million in Q3 2025, $52.3 million for Q2 2025, and $25.5 million during Q1 2025.